Barnidipine ameliorates the vascular and renal injury in L-NAME-induced hypertensive rats

Eur J Pharmacol. 2015 Oct 5:764:433-442. doi: 10.1016/j.ejphar.2015.07.033. Epub 2015 Jul 14.

Abstract

The present study was aimed to investigate the influence of Barnidipine treatment on early stage hypertension by determining the function and morphology of the mesenteric and renal arteries as well as the kidney in N(ω)-Nitro-L-Arginine Methyl Ester (L-NAME)-induced hypertensive rats. Barnidipine (3 mg/kg/day p.o) was applied to rats after 2 weeks of L-NAME (60 mg/kg/day) administration, and continued for the next 3 weeks concomitantly with L-NAME. The systolic blood pressure (SBP) of rats was determined to decrease significantly in Barnidipine treated hypertensive group when compared to that of rats received L-NAME alone. Myograph studies demonstrated that the contractile reactivity to noradrenaline were significantly reduced in both of the resistance arteries while endothelium-dependent relaxations to acethylcholine were significantly diminished particularly in the mesenteric arteries of L-NAME-induced hypertensive rats. The impaired contractile and endothelial responses were completely restored by concomitant treatment of Barnidipine with L-NAME. Histopathological examinations verified structural alterations in the arteries as well as the kidney. Moreover, a decrease in endothelial nitric oxide synthase (eNOS) expression was presented both in the arteries and kidney of hypertensive rats which were increased following Barnidipine treatment. Elevated plasma levels of malondialdehyde (MDA) and myeloperoxidase (MPO) were also reduced in Barnidipine treated hypertensive rats. In conclusion, besides to its efficacy in reducing the elevated SBP, amelioration of vascular function, modulation of arterial and renal eNOS expressions as well as reduction of the plasma levels of oxidative and inflammatory biomarkers are possible supportive mechanisms mediating the favorable implications of Barnidipine in L-NAME-induced hypertension model.

Keywords: Barnidipine; Kidney; Mesenteric artery; Renal artery; l-NAME-induced hypertension.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antihypertensive Agents / pharmacology*
  • Blood Pressure / drug effects
  • Calcium Channel Blockers / pharmacology*
  • Cytoprotection
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Hypertension / chemically induced
  • Hypertension / drug therapy*
  • Hypertension / metabolism
  • Hypertension / pathology
  • Hypertension / physiopathology
  • Inflammation Mediators / metabolism
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney Diseases / chemically induced
  • Kidney Diseases / metabolism
  • Kidney Diseases / pathology
  • Kidney Diseases / physiopathology
  • Kidney Diseases / prevention & control*
  • Male
  • Malondialdehyde / metabolism
  • Mesenteric Arteries / drug effects*
  • Mesenteric Arteries / metabolism
  • Mesenteric Arteries / pathology
  • Mesenteric Arteries / physiopathology
  • NG-Nitroarginine Methyl Ester*
  • Nifedipine / analogs & derivatives*
  • Nifedipine / pharmacology
  • Nitric Oxide Synthase Type III / metabolism
  • Oxidative Stress / drug effects
  • Peroxidase / metabolism
  • Rats, Wistar
  • Renal Artery / drug effects*
  • Renal Artery / metabolism
  • Renal Artery / pathology
  • Renal Artery / physiopathology
  • Time Factors
  • Vascular Remodeling / drug effects
  • Vasoconstriction / drug effects
  • Vasodilation / drug effects

Substances

  • Antihypertensive Agents
  • Calcium Channel Blockers
  • Inflammation Mediators
  • mepirodipine
  • Malondialdehyde
  • Peroxidase
  • Nitric Oxide Synthase Type III
  • Nos3 protein, rat
  • Nifedipine
  • NG-Nitroarginine Methyl Ester